Discounts at partner companies

How susceptible are you to certain illnesses?

Pill Protect

Could I develop thrombosis from taking oral contraceptives? Is there a risk of my unborn child suffering a genetic disorder? How high is the risk of cancer in my family? Take a test to see if you or your family are affected.

Detecting the risk of thrombosis (Pill Protect)

In recent years, around 400 cases of thrombosis have been reported to Swissmedic, the Swiss Agency for Therapeutic Products, every year. All of these cases were caused by taking oral contraceptives.

Thrombosis occurs if a blood clot forms in a blood vessel. The flow of blood through the circulatory system is blocked. As a result, the blood can no longer easily flow back to the heart and lungs and a blockage forms. Thanks to the Pill Protect test, you can find out about your personal risk of developing venous thrombosis as a result of taking the contraceptive pill. The results of the test help you to find the suitable contraceptive pill or an alternative method of contraception together with your doctor.

The genetic test only needs to be carried out once. Your general practitioner just has to take a simple saliva sample.

Limits of Pill Protect

Pill Protect can determine the risk of thrombosis only in connection with oral contraceptives. The test cannot offer general security. There can also be a risk of venous thrombosis with other treatments. The risk of thrombosis can therefore never be completely ruled out.

When selecting the suitable method of contraception, the health of the patient as well as other laboratory tests carried out by the doctor also play an important role.

Clinical studies

A clinical study was carried out on 1,600 women who take an oral contraceptive. Half of these women developed thrombosis. Of these cases, the Pill Protect test was able to identify six times as many women who developed thrombosis than with the usual procedure based on a medical questionnaire.

Costs covered with PRIMEO supplementary insurance

If you have taken out PRIMEO supplementary insurance, Helsana will cover 90% of the costs of the Pill Protect test offered by partner firm Gene Predictis. Supplementary insurance pays up to CHF 5,000 in total per calendar year for innovative forms of diagnosis and treatment. Helsana will be invoiced directly for your test. To be eligible for the test, you must be a Primeo policyholder between the ages of 15 and 49.

Costs covered without PRIMEO supplementary insurance

This laboratory test is not covered by basic insurance. For policyholders without PRIMEO supplementary insurance, Helsana has agreed a preferential price with partner firm Gene Predictis. Customers without supplementary insurance can have the test at a 20% discount on the official price. The policyholder will be invoiced directly for the test.

Discounts on further Gene Predictis services

Helsana Group policyholders benefit from a 10% discount on further laboratory services from partner firm Gene Predictis.

Further information

Non-invasive prenatal test to determine genetic disorders (NIP test)

From as early as the ninth week of pregnancy, non-invasive prenatal tests can determine with a high level of certainty whether an unborn child has a genetic disorder such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) or trisomy 13 (Patau syndrome). They provide pregnant women with a valuable tool to help them decide whether or not to undergo additional invasive examinations.

As of mid-July 2015, this examination (trisomy 21, 18 and 13) has been covered by basic insurance, provided the requirements of the Health Care Benefits Ordinance (KLV) are met. For more detailed information, please consult your attending physician.

Various test options

Our partners Genetica and LifeCodexx AG offer various test options. The options offered by Genetica are Panorama Basic or Panorama Plus. LifeCodexx AG offers three test options: PraenaTest 1, 2 and 3.

Helsana has agreed favourable conditions with partners Genetica and LifeCodexx. Genetica grants a 12% discount on the official prices of the Panorama tests (Panorama Basic and Panorama Plus), while a fixed price reduction has been agreed with LifeCodexx AG for PraenaTest 1, 2 and 3.

Costs covered with PRIMEO supplementary insurance

If the requirements for persons with basic insurance under the KLV are not met and you have taken out PRIMEO supplementary insurance, Helsana will pay for the NIP test provided it is the Panorama or Praena test offered by our partner firms Genetica und LifeCodexx. Under PRIMEO supplementary insurance, 90% of the costs of prenatal tests are assumed by Helsana, up to a maximum of CHF 5,000 per calendar year. The billing of services is concluded directly between Genetica or indirectly between LifeCodexx AG and Helsana.

Detecting hereditary forms of cancer (myRisk)

5 to 10% of all cancers are hereditary, i.e. caused by mutations in our genes. People who undergo such a mutation have a significantly higher risk of developing cancer. Since the mutations can be inherited, cancer cases often occur in clusters in the families affected. A genetic test can offer clarity and confirm the presence of mutations, thereby providing important information on treatment and prevention.

Benefits of the myRisk diagnostic panel

A single gene mutation can increase the risk of multiple forms of cancer. A mutation in the BRCA2 gene, for example, increases the risk of breast, ovarian, prostate and pancreatic cancer, as well as the risk of developing a melanoma. At the same time, cancer can be caused by changes to several genes. For this reason, it is sometimes useful to examine all relevant genes at once as part of a so-called diagnostic panel.

The myRisk test is an analysis of 28 genes which can contribute to the development of eight different forms of cancer: breast cancer, ovarian cancer, uterine cancer, prostate cancer, pancreatic cancer, stomach cancer, bowel cancer and melanoma. The myRisk test can be used to clearly determine the risk of cancer for most mutations identified. All that is required is a blood test.

If a mutation is discovered, medical care can be adapted accordingly. Specialised care programmes help detect the cancer at an early stage – when the chances of recovery are high – or even prevent its onset. This can be invaluable for first-degree family members (parents, siblings and children), who have a 50% probability of also carrying the mutation.

Limits of myRisk

The myRisk test enables mutations to be detected in the examined genes and individualised treatment or monitoring strategies to be determined. Please note:

  • For certain mutations, information on links to cancer is scarce. As soon as new information on the harmfulness of these mutations becomes available, your doctor will be informed immediately.
  • A negative test result (no mutation) does not always mean that there is a lower risk of cancer. If a cluster of cancer cases is known to have occurred in the family but no mutations are present, the risk of cancer may still be high.
  • Conversely, if a mutation is detected, it is possible that cancer may never develop.
Clinical studies

The myRisk test is performed using the latest available technology. Studies have shown that the test can reliably identify all forms of DNA mutations. The process for interpreting the data is also of high quality. In addition, the laboratory conducting the test has been involved in over 450 publications related to hereditary cancer in the last five years.

Costs covered with PRIMEO supplementary insurance

If you have taken out PRIMEO supplementary insurance, Helsana will cover 90% of the costs of the myRisk test offered by partner firm Myriad. Supplementary insurance pays up to CHF 5,000 in total per calendar year for innovative forms of diagnosis and treatment. Helsana will be invoiced directly for your test. To be eligible for the test, you must be a PRIMEO policyholder over 18 years of age.

Costs covered without PRIMEO supplementary insurance

This laboratory test is not covered by basic insurance. For policyholders without PRIMEO supplementary insurance, Helsana has agreed a preferential price with partner firm Myriad. Customers without supplementary insurance can have the test at a 20% discount on the official price. The policyholder will be invoiced directly for the test.

Advice from your general practitioner

If you are interested in one of these tests, obtain advice from your doctor. The analysis of the blood, tissue or saliva sample is only carried out if prescribed by a doctor. The partner firms make the results directly available to the doctor.